Galapagos NV ADR (GLPG)vsJohnson & Johnson (JNJ)
GLPG
Galapagos NV ADR
$27.86
-1.97%
HEALTHCARE · Cap: $1.91B
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 8564% more annual revenue ($96.36B vs $1.11B). GLPG leads profitability with a 28.8% profit margin vs 21.8%. GLPG trades at a lower P/E of 5.0x. GLPG earns a higher WallStSmart Score of 74/100 (B).
GLPG
Strong Buy74
out of 100
Grade: B
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.3%
Fair Value
$316.70
Current Price
$27.86
$288.84 discount
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Strong operational efficiency at 88.0%
Revenue surging 1093.0% year-over-year
Earnings expanding 3036.0% YoY
Keeps 29 of every $100 in revenue as profit
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Trading at 9.6x book value
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : GLPG
The strongest argument for GLPG centers on P/E Ratio, Operating Margin, Revenue Growth. Profitability is solid with margins at 28.8% and operating margin at 88.0%. Revenue growth of 1093.0% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : GLPG
The primary concerns for GLPG are Price/Book, Market Cap, Free Cash Flow.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
GLPG profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.33 — expect wider price swings.
GLPG is growing revenue faster at 1093.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
GLPG scores higher overall (74/100 vs 59/100), backed by strong 28.8% margins and 1093.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Galapagos NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?